CRL Charles River: Earnings growth forecast for next year

CRL (criver.com) - company brandmark

Charles River Laboratories (CRL) strives for dominance in the primary drug development segment, although this path requires a highly specialized staff of toxicologists and AI experts. The consensus EPS growth forecast for next year reconciles these ambitions with personnel costs, where the value of 12.50 determines this level. Stability is ensured by strict FDA oversight, which transforms long-term contracts with industry behemoths into a reliable profit generator.

CRL: Charles River Laboratories International, Inc. Expected earnings per share trend next year 07/04/2022 - 11/14/2026

Charles River Laboratories International, Inc. - analytical breakdowns and key metrics (CRL)

- price and consensus price forecast:
Price Chart criver.com|CRL - Analyst Median Target
- company stock capitalization data:
Market Capitalization Charles River Lab|CRL - Real Price to Acquire Entire Company
- book capitalization indicators:
Book Value per Share Charles River|CRL - Accounting Value of Company|Market Capitalization to Book Value Ratio criver.com|CRL - Company Total Assets
- company liabilities and liquidity data:
Debt to Equity Charles River Laboratories|CRL - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Charles River Lab|CRL - Company Debts|Debts to Book Capitalization Charles River|CRL - Long-Term Debt|Company Short-Term Debt Charles River|Quick Liquidity Indicator criver.com
- earnings and valuation multiples information:
CRL - Final Profit|Expected Profit Charles River Laboratories|CRL - Company Value to Net Income|Forward P/E Multiple Charles River Laboratories International, Inc.|CRL - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Charles River Laboratories International, Inc.|CRL - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Charles River|CRL - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months criver.com|CRL - Earnings per share increase in current year|Expected earnings per share growth for next year Charles River Laboratories
- sales and revenue indicators:
CRL - Company Sales Revenue|Company Projected Revenue Charles River Laboratories|CRL - Price-to-Revenue Ratio|Forward P/S Multiple Charles River Laboratories
Summary company analysis:Charles River Laboratories International, Inc., CRL
Core merchandise of Charles River

Charles River Laboratories (CRL) maintains a steady stream of orders due to its status as a hidden monopolist in the preclinical testing sector, a trend reflected in the consensus EPS forecasts for the coming year. This indicator aggregates market expectations for net profit growth rates, allowing investors to assess the fundamental resilience of the business and the accuracy of the company's capitalization amid evolving drug safety requirements.

Competitors of Charles River Laboratories

Net earnings per share growth forecast for next year iqvia.com|Net earnings per share growth forecast for next year LH|Net earnings per share growth forecast for next year Medpace Holdings (MEDP)|Consensus forecast of earnings per share growth for next year ICON Public Limited Company|Evotec Corp - Expected earnings per share growth for next year|FTRE (Fortrea Clinical) - Net earnings per share change forecast for next year|Lifecore Biomedical Inc. - Earnings growth forecast for next year|omniab.com (OABI) - Expected earnings per share growth for next year|Inotiv Corporation (NOTV) - Net earnings per share growth forecast for next year|CDMO - Consensus forecast of earnings per share growth for next year|CTLT (Catalent Inc.) - Earnings growth forecast for next year|SCPX: Expected earnings per share trend next year